



June 27, 2025

**Re : Updated information regarding ZENHALE® (mometasone furoate and formoterol fumarate dihydrate) – DINs: 02361752 and 02361760**

Dear Healthcare Professional,

This letter is to inform you of a change in indication to Organon's drug product, ZENHALE® (mometasone furoate and formoterol fumarate dihydrate).

ZENHALE® is indicated for:

- the treatment of asthma, in patients 12 years of age and older with reversible obstructive airway disease.

ZENHALE® was previously also indicated for the treatment of asthma, in patients 5 years of age and older with reversible obstructive airway disease. The change in the ZENHALE® indication was due to the marketing status alteration of ZENHALE® 50 mcg / 5 mcg per actuation strength, which was discontinued post-market (DIN Deletion) as of September 30, 2022. Consequently, the ZENHALE® Product Monograph was revised accordingly.

For the complete prescribing information and information available for the patients/caregivers please consult the [ZENHALE® Product Monograph](#). The Product Monograph can be found on the [Organon Website](#), or by contacting Organon Canada at 1-844-820-5468.

Should you have medical enquiries regarding ZENHALE®, please contact our Medical Information Department at 1-844-820-5468 or [medinfocanada@organon.com](mailto:medinfocanada@organon.com).

® N.V. Organon. Used under license.